Drugs@FDA document
BUPRENORPHINE; NALOXONE Letter · ANDA 209831 ORIG-1
Drugs@FDA document · TEVA PHARMS USA · Aug 20, 2018
Key facts
| Drug name | BUPRENORPHINE; NALOXONE |
|---|---|
| Document type | Letter |
| Application | ANDA209831 |
| Submission | ORIG-1 |
| Company | TEVA PHARMS USA |
| Document date | Aug 20, 2018 |
| FDA document | accessdata.fda.gov |
At a glance
- 1–9 Documents for this application
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: